MORGAN STANLEY RESEARCH ASIA/PACIFIC

Morgan Stanley India Company Private Limited+

Vipin Khare Vipin.Khare@morganstanley.com

+91 22 6118 2236 **Gaurav Rateria**

Gaurav.Rateria@morganstanley.com +91 22 6118 2237

October 21, 2011

Stock Rating Equal-weight Industry View In-Line

Info Edge (India) Ltd. Strong Sep-11 standalone performance subsidizing subsidiaries' losses; EW

Quick Comment: Info Edge management indicated that India's slowing GDP growth could hit its hiring business with a lag. Management also indicated that it has seen clients deferring hiring decisions and taking lower-priced/shorter-duration products amid macroeconomic uncertainty.

Strong Sep-11 results: Revenues were Rs910m (+5.1% qoq, +31% yoy). EBIT margin was 33.4% (-70bps qoq, +540bps yoy). Net profit of Rs282m (+10% qoq, +58% yoy) was ahead of estimates.

Segmental performance: Recruitment business reported revenue growth of +6.7% gog. However, revenues from other businesses declined -2.4% gog, a drag on overall revenue growth for the company. EBITDA margins for recruitment business remain at healthy levels of 48.6% (-40bps qoq), while losses in other businesses increased gog.

More clarity on subsidiaries' losses: Management indicated that revenues and losses in subsidiaries could increase yoy in FY12e. Management expects revenues of its subsidiaries to double in FY12e. We estimate losses in subsidiaries could be towards the lower end of ~Rs200-Rs300m in the current year.

We maintain our FY12e net profit forecast of Rs979m (+55% yoy): However, if the subsidiaries' losses for FY12e turn out to be significantly higher than our current forecast of ~Rs200m, then our FY12e-14e estimates could have downward bias.

We recommend waiting for a better entry opportunity: On a consolidated basis, the stock currently trades at ~42x FY12e and ~34x FY13e EPS estimates. Given the cautious management commentary and slowing growth rates, we maintain our EW rating.

Key Ratios and Statistics

Reuters: INED.BO Bloomberg: INFOE IN

India Internet Services				
Shr price, close (Oct 20, 2011)	Rs700.10			
52-Week Range	Rs772.00-460.35			
Sh out, dil, curr (mn)	55			
Mkt cap, curr (mn)	Rs38,222			s38,222
EV, curr (mn)	Rs33,525			
Avg daily trading value (mn)				Rs21
Fiscal Year ending	03/11	03/12e	03/13e	03/14e
ModelWare EPS (Rs)	11.50	17.93	21.98	26.35
Consensus EPS (Rs)§	13.42	18.57	22.34	25.78
Revenue, net (Rs mn)	3,217	4,182	5,228	6,378
EBITDA (Rs mn)	828	1,198	1,495	1,799
ModelWare net inc (Rs mn)	628	979	1,200	1,438
P/E	58.0	39.1	31.8	26.6
P/BV	8.4	7.3	6.0	5.0
RNOA (%)	(250.6)	(227.1)	(271.7)	(308.8)
ROE (%)	16.8	22.5	22.8	22.6
EV/EBITDA	38.4	27.2	21.1	16.5
Div yld (%)	0.1	0.2	0.2	0.3
FCF yld ratio (%)	0.5	0.8	1.1	2.5
Leverage (EOP) (%)	(107.9)	(106.6)	(105.7)	(111.0)

Unless otherwise noted, all metrics are based on Morgan Stanley ModelWare

framework (please see explanation later in this note). § = Consensus data is provided by FactSet Estimates

e = Morgan Stanley Research estimates

Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report.

+= Analysts employed by non-U.S. affiliates are not registered with FINRA, may not be associated persons of the member and may not be subject to NASD/NYSE restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

October 21, 2011 Info Edge (India) Ltd.

Exhibit 1 Info Edge: Sep-11 Standalone income statement (Rs m, %)

Commen	% yoy	% qoq	Sep-11	Jun-11	Sep-10	Year to Mar (Rs m)
evenues from Other business verticals declined first time						
last 7 quarte	28.0%	5.1%	911	867	712	Revenues
	18.1%	6.9%	589	550	498	Costs
	-15.4%	-5.8%	22	23	26	Network charges
	21.6%	0.4%	329	327	270	Staff Costs
d expenses have historically declined qoq in 3Q ; Lower a						
expenses in 3Q12 could help margins q	31.1%	31.7%	146	111	112	Advertising costs
	1.5%	3.2%	91	88	90	Other admin costs
	50.9%	2.0%	322	316	214	EBITDA
	538bps	-109bps	35.4%	36.5%	30.0%	Margins(%)
	28.2%	-13.2%	18	21	14	Depreciation
	52.5%	3.0%	304	295	200	EBIT
	537bps	-68bps	33.4%	34.1%	28.0%	Margins(%)
	39.9%	17.1%	92	79	66	Other income
	49.4%	6.0%	396	374	265	PBT
	31.9%	-3.3%	114	118	86	Tax expense
	-382 <i>bps</i>	-276bps	28.8%	31.5%	32.6%	Effective tax rate (%)
	57.9%	10.3%	282	256	179	PAT
	587bps	144bps	31.0%	29.6%	25.1%	Margins(%)
	57.6%	10.2%	5.2	4.7	3.3	Basic EPS (Rs)

Info Edge (Rs m)	Sep-10	Jun-11	Sep-11	% qoq	% уоу
Revenues (Rs m)					
Recruitment vertical	590	700	747	6.7%	26.6%
Other verticals	122	167	163	-2.4%	33.6%
Total	712	867	910	5.0%	27.8%
EBITDA (Rs m)					
Recruitment vertical	273	343	363	5.8%	33.1%
Other verticals	(59)	(27)	(41)	51.9%	-30.5%
Total	214	316	322	1.8%	50.7%
EBITDA margins (%)	Sep-10	Jun-11	Sep-11	qoq bps	yoy bps
Recruitment vertical	46.2%	49.0%	48.6%	(41)	238
Other verticals	-48.4%	-16.2%	-25.2%	(899)	2,321
Total	30.0%	36.5%	35.4%	(109)	537

Source: Company data, Morgan Stanley Research

MORGAN STANLEY RESEARCH

October 21, 2011 Info Edge (India) Ltd.

MORGAN STANLEY

ModelWare

Morgan Stanley ModelWare is a proprietary analytic framework that helps clients uncover value, adjusting for distortions and ambiguities created by local accounting regulations. For example, ModelWare EPS adjusts for one-time events, capitalizes operating leases (where their use is significant), and converts inventory from LIFO costing to a FIFO basis. ModelWare also emphasizes the separation of operating performance of a company from its financing for a more complete view of how a company generates earnings.

Disclosure Section responsibility for its contents) and/or Morgan Stanley Research were prepared or are disseminated by Morgan Stanley Asia Limited (which accepts the (Singapore) Securities Pte Ltd (Registration number 20008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research), and/or Morgan Stanley Taiwan Limited and/or Morgan Stanley & Co International plc, Seoul Branch, and/or Morgan Stanley Research), 67 003 734 576, holder of Australian financial services license No. 233742, which accepts responsibility for its contents), and/or Morgan Stanley India Company Private Limited and their affiliates (collectively, "Morgan Stanley"). For important disclosures, stock price charts and equity rating histories regarding companies that are the subject of this report, please see the Morgan Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Stanley Research Disclosure Website at www.morganstanley.com/researchdisclosures, or contact your investment representative or Morgan Stanley Research at 1585 Broadway, (Attention: Research Management), New York, NY, 10036 USA. Analyst Certification

Analyst Certification

The following analysts hereby certify that their views about the companies and their securities discussed in this report are accurately expressed and that they have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report: Vipin Khare.

Unless otherwise stated, the individuals listed on the cover page of this report are research analysts.

Global Research Conflict Management Policy

Morgan Stanley Research has been published in accordance with our conflict management policy, which is available at www.morganstanley.com/institutional/research/conflictpolicies.

Important US Regulatory Disclosures on Subject Companies

As of September 30, 2011, Morgan Stanley beneficially owned 1% or more of a class of common equity securities of the following companies covered in Morgan Stanley Research: Info Edge (India) Ltd., MakeMyTrip Limited.

Within the last 12 months, Morgan Stanley has received compensation for investment banking services from MakeMyTrip Limited. Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from Info Edge (India) Ltd.

Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following company: Info Edge (India) Ltd.. Morgan Stanley & Co. LLC makes a market in the securities of MakeMyTrip Limited.

The equity research analysts or strategists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment

Morgan Stanley and its affiliates do business that relates to companies/instruments covered in Morgan Stanley Research, including market making, providing liquidity and specialized trading, risk arbitrage and other proprietary trading, fund management, commercial banking, extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Stanley and extension of credit, investment services and investment banking. Morgan Stanley sells to and buys from customers the securities/instruments of companies covered in Stanley and the securities/instruments of compa Morgan Stanley Research on a principal basis. Morgan Stanley may have a position in the debt of the Company or instruments discussed in this report. Certain disclosures listed above are also for compliance with applicable regulations in non-US jurisdictions.

STOCK RATINGS

Morgan Stanley uses a relative rating system using terms such as Overweight, Equal-weight, Not-Rated or Underweight (see definitions below). Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold and sell. Investors should carefully read the definitions of all ratings used in Morgan Stanley Research. In addition, since Morgan Stanley Research contains more complete information concerning the analyst's views, investors should carefully read Morgan Stanley Research, in its entirety, and not infer the contents from the rating alone. In any case, ratings (or research) should not be used or relied upon as investment advice. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations.

Global Stock Ratings Distribution

(as of September 30, 2011)

For disclosure purposes only (in accordance with NASD and NYSE requirements), we include the category headings of Buy, Hold, and Sell alongside our ratings of Overweight, Equal-weight, Not-Rated and Underweight. Morgan Stanley does not assign ratings of Buy, Hold or Sell to the stocks we cover. Overweight, Equal-weight, Not-Rated and Underweight are not the equivalent of buy, hold, and sell but represent recommended relative weightings (see definitions below). To satisfy regulatory requirements, we correspond Overweight, our most positive stock rating, with a buy recommendation; we correspond Equal-weight and Not-Rated to hold and Underweight to sell recommendations, respectively.

October 21, 2011 Info Edge (India) Ltd.

	Coverage Universe		Investment Banking Clients (IBC)			
-	% of		% of		% of Rating	
Stock Rating Category	Count	Total	Count	Total IBC	Category	
Overweight/Buy	1130	40%	457	46%	40%	
Equal-weight/Hold	1168	42%	419	42%	36%	
Not-Rated/Hold	112	4%	23	2%	21%	
Underweight/Sell	400	14%	104	10%	26%	
Total	2,810		1003			

Data include common stock and ADRs currently assigned ratings. An investor's decision to buy or sell a stock should depend on individual circumstances (such as the investor's existing holdings) and other considerations. Investment Banking Clients are companies from whom Morgan Stanley received investment banking compensation in the last 12 months.

Analyst Stock Ratings

Overweight (O or Over) - The stock's total return is expected to exceed the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months. Equal-weight (E or Equal) - The stock's total return is expected to be in line with the total return of the relevant country MSCI Index, on a risk-adjusted basis over the next 12-18 months.

Not-Rated (NR) - Currently the analyst does not have adequate conviction about the stock's total return relative to the relevant country MSCI Index on a risk-adjusted basis, over the next 12-18 months.

Underweight (U or Under) - The stock's total return is expected to be below the total return of the relevant country MSCI Index, on a risk-adjusted basis, over the next 12-18 months.

Unless otherwise specified, the time frame for price targets included in Morgan Stanley Research is 12 to 18 months.


Analyst Industry Views

Attractive (A): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be attractive vs. the relevant broad market benchmark, as indicated below.

In-Line (I): The analyst expects the performance of his or her industry coverage universe over the next 12-18 months to be in line with the relevant broad market benchmark, as indicated below. Cautious (C): The analyst views the performance of his or her industry coverage universe over the next 12-18 months with caution vs. the relevant

broad market benchmark, as indicated below. Benchmarks for each region are as follows: North America - S&P 500; Latin America - relevant MSCI country index or MSCI Latin America Index; Europe - MSCI Europe; Japan - TOPIX; Asia - relevant MSCI country index.

Stock Price, Price Target and Rating History (See Rating Definitions)





Stock Rating History: 12/12/08 : U/I; 11/9/09 : 0/I; 10/26/10 : E/I; 1/21/11 : 0/I; 4/29/11 : E/I Price Target History: 12/12/08 : 157.5; 7/24/09 : 180; 11/9/09 : 442.5; 5/19/10 : 537.5; 10/26/10 : 675

Date Format : MM/DD/YY No Price Target Assigned (NA) Source: Morgan Stanley Research Price Target --Stock Price (Not Covered by Current Analyst) --- Stock Price (Covered by Current Analyst) = Stock and Industry Ratings (abbreviations below) appear as + Stock Rating/Industry View Stock Ratings: Overweight (O) Equal-weight (E) Underweight (U) Not-Rated (NR) More Volatile (V) No Rating Available (NA) Industry View: Attractive (A) In-line (I) Cautious (C) No Rating (NR)

MORGAN STANLEY RESEARCH

October 21, 2011 Info Edge (India) Ltd.

Important Disclosures for Morgan Stanley Smith Barney LLC Customers

Citi Investment Research & Analysis (CIRA) research reports may be available about the companies or topics that are the subject of Morgan Stanley Research. Ask your Financial Advisor or use Research Center to view any available CIRA research reports in addition to Morgan Stanley research reports.

Important disclosures regarding the relationship between the companies that are the subject of Morgan Stanley Research and Morgan Stanley Smith Barney LLC, Morgan Stanley and Citigroup Global Markets Inc. or any of their affiliates, are available on the Morgan Stanley Smith Barney disclosure website at www.morganstanleysmithbarney.com/researchdisclosures.

For Morgan Stanley and Citigroup Global Markets, Inc. specific disclosures, you may refer to www.morganstanley.com/researchdisclosures and https://www.citigroupgeo.com/geopublic/Disclosures/index_a.html.

Each Morgan Stanley Equity Research report is reviewed and approved on behalf of Morgan Stanley Smith Barney LLC. This review and approval is conducted by the same person who reviews the Equity Research report on behalf of Morgan Stanley. This could create a conflict of interest.

Other Important Disclosures

Morgan Stanley is not acting as a municipal advisor and the opinions or views contained herein are not intended to be, and do not constitute, advice within the meaning of Section 975 of the Dodd-Frank Wall Street Reform and Consumer Protection Act.

Morgan Stanley produces an equity research product called a "Tactical Idea." Views contained in a "Tactical Idea" on a particular stock may be contrary to the recommendations or views expressed in research on the same stock. This may be the result of differing time horizons, methodologies, market events, or other factors. For all research available on a particular stock, please contact your sales representative or go to Client Link at www.morganstanley.com.

Morgan Stanley Research does not provide individually tailored investment advice. Morgan Stanley Research has been prepared without regard to the individual financial circumstances and objectives of persons who receive it. Morgan Stanley recommends that investors independently evaluate particular investments and strategies, and encourages investors to seek the advice of a financial adviser. The appropriateness of a particular investment or strategy will depend on an investor's individual circumstances and objectives. The securities, instruments, or strategies discussed in Morgan Stanley Research may not be suitable for all investors, and certain investors may not be eligible to purchase or participate in some or all of them.

The fixed income research analysts, strategists or economists principally responsible for the preparation of Morgan Stanley Research have received compensation based upon various factors, including quality, accuracy and value of research, firm profitability or revenues (which include fixed income trading and capital markets profitability or revenues), client feedback and competitive factors. Fixed Income Research analysts', strategists' or economists' compensation is not linked to investment banking or capital markets transactions performed by Morgan Stanley or the profitability or revenues of particular trading desks.

Morgan Stanley Research is not an offer to buy or sell or the solicitation of an offer to buy or sell any security/instrument or to participate in any particular trading strategy. The "Important US Regulatory Disclosures on Subject Companies" section in Morgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more in portant OS regulatory Discussions on Subject Companies. Section in Worgan Stanley Research lists all companies mentioned where Morgan Stanley owns 1% or more of a class of common equity securities of the companies. For all other companies mentioned in Morgan Stanley Research, Morgan Stanley may have an investment of less than 1% in securities/instruments or derivatives of securities/instruments of companies and may trade them in ways different from those discussed in Morgan Stanley Research. Employees of Morgan Stanley not involved in the preparation of Morgan Stanley Research may have investments in securities/instruments of companies mentioned and may trade them in ways different from those discussed in Morgan Stanley Research. Derivatives may be issued by Morgan Stanley or associated persons.

With the exception of information regarding Morgan Stanley, Morgan Stanley Research is based on public information. Morgan Stanley makes every effort to use reliable, comprehensive information, but we make no representation that it is accurate or complete. We have no obligation to tell you when opinions or information in Morgan Stanley Research change apart from when we intend to discontinue equity research coverage of a subject company. Facts and views presented in Morgan Stanley Research have not been reviewed by, and may not reflect information known to, professionals in other Morgan Stanley business areas, including investment banking personnel.

Morgan Stanley Research personnel may participate in company events such as site visits and are generally prohibited from accepting payment by the company of associated expenses unless pre-approved by authorized members of Research management.

The value of and income from your investments may vary because of changes in interest rates, foreign exchange rates, default rates, prepayment rates, securities/instruments prices, market indexes, operational or financial conditions of companies or other factors. There may be time limitations on the exercise of options or other rights in securities/instruments transactions. Past performance is not necessarily a guide to future performance. Estimates of future performance are based on assumptions that may not be realized. If provided, and unless otherwise stated, the closing price on the cover page is that of the primary exchange for the subject company's securities/instruments.

Morgan Stanley may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

To our readers in Taiwan: Information on securities/instruments that trade in Taiwan is distributed by Morgan Stanley Taiwan: Information on securities/instruments issued by a company owned by the government of or incorporated in the PRC and listed in on the Stock Exchange of Hong Kong ("SEHK"), namely the H-shares, including the component company stocks of the Stock Exchange of Hong Kong ("SEHK") hang Seng China Enterprises ("SEEK"). The reader should independently evaluate the investment risks and is solely responsible for their investment decisions. Morgan Stanley Research may not be distributed to the public media or quoted or used by the public media without the express written consent of Morgan Stanley. Information on securities/instruments that do not trade in Taiwan is for informational purposes only and is not to be construed as a recommendation or a solicitation to trade in such securities/instruments. MSTL may not execute transactions for clients in these securities/instruments.

To our readers in Hong Kong: Information is distributed in Hong Kong by and on behalf of, and is attributable to, Morgan Stanley Asia Limited as part of its regulated activities in Hong Kong. If you have any queries concerning Morgan Stanley Research, please contact our Hong Kong sales representatives.

Certain information in Morgan Stanley Research was sourced by employees of the Shanghai Representative Office of Morgan Stanley Asia Limited for the use of Morgan Stanley Asia Limited.

Morgan Stanley is not incorporated under PRC law and the research in relation to this report is conducted outside the PRC. Morgan Stanley Research does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves.

an oner to sen or the somethation of an oner to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. Morgan Stanley Research is disseminated in Brazil by Morgan Stanley C.T.V.M. S.A.; in Japan by Morgan Stanley MUFG Securities Co., Ltd. and, for Commodities related research reports only, Morgan Stanley Capital Group Japan Co., Ltd; in Hong Kong by Morgan Stanley Asia Limited (which accepts responsibility for its contents); in 30008434H), regulated by the Monetary Authority of Singapore (which accepts legal responsibility for its contents and should be contacted with respect to any matters arising from, or in connection with, Morgan Stanley Research); in Australia to "wholesale clients" within the meaning of the Australian Corporations Act by Morgan Stanley Australia Limited A.B.N. 67 003 734 576, holder of Australian Groporations Act by Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian Groporations Act by Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian Groporations Act by Morgan Stanley Smith Barney Australia Pty Ltd (A.B.N. 19 009 145 555, holder of Australian Groporations Act by Morgan Stanley Canada Limited, A.B. 10003 Stanley Research in Canada by Morgan Stanley Canada Limited, A.B. 19 009 145 555, holder of Australian Groporations Stanley Barney Stanley Research in Canada by Morgan Stanley Canada Limited, which has approved of, and has agreed to take responsibility for its contents; in Spain by Morgan Stanley S.V., S.A., a Morgan Stanley group company, which is supervised by the Spanish Securities Markets Commission (CNMV) and states that Morgan Stanley Research has been written and distributed in acceptare seponsibility for its contents. Morgan Stanley Research has been written and distributed in accepta

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (DIFC Branch), regulated by the Dubai Financial Services Authority (the DFSA), and is directed at Professional Clients only, as defined by the DFSA. The financial products or financial services to which this research relates will only be made available to a customer who we are satisfied meets the regulatory criteria to be a Professional Client.

MORGAN STANLEY RESEARCH

October 21, 2011 Info Edge (India) Ltd.

The information in Morgan Stanley Research is being communicated by Morgan Stanley & Co. International plc (QFC Branch), regulated by the Qatar Financial Centre Regulatory Authority (the QFCRA), and is directed at business customers and market counterparties only and is not intended for Retail Customers as defined by the QFCRA.

As required by the Capital Markets Board of Turkey, investment information, comments and recommendations stated here, are not within the scope of investment advisory activity. Investment advisory service is provided in accordance with a contract of engagement on investment advisory concluded between brokerage houses, portfolio management companies, non-deposit banks and clients. Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences. For this reason, to make an investment decision by relying solely to this information stated here may not bring about outcomes that fit your expectations.

The trademarks and service marks contained in Morgan Stanley Research are the property of their respective owners. Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data. The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI and S&P.

Morgan Stanley has based its projections, opinions, forecasts and trading strategies regarding the MSCI Country Index Series solely on publicly available information. MSCI has not reviewed, approved or endorsed the projections, opinions, forecasts and trading strategies contained herein. Morgan Stanley has no influence on or control over MSCI's index compilation decisions.

Morgan Stanley Research, or any portion thereof may not be reprinted, sold or redistributed without the written consent of Morgan Stanley.

Morgan Stanley Research is disseminated and available primarily electronically, and, in some cases, in printed form.

Additional information on recommended securities/instruments is available on request.

The Americas 1585 Broadway New York, NY 10036-8293 **United States** Tel: +1 (1) 212 761 4000 Europe 20 Bank Street, Canary Wharf London E14 4AD United Kingdom Tel: +44 (0) 20 7 425 8000 Japan 4-20-3 Ebisu, Shibuya-ku Tokyo 150-6008 Japan Tel: +81 (0) 3 5424 5000 Asia/Pacific 1 Austin Road West Kowloon Hong Kong Tel: +852 2848 5200

Industry Coverage:India Internet Services

Company (Ticker)	Rating (as of) Price* (10/20/2011)			
Vipin Khare				
Info Edge (India) Ltd. (INED.BO)	E (04/29/2011)	Rs700.1		
MakeMyTrip Limited (MMYT.O)	E (09/21/2010)	US\$27.55		

Stock Ratings are subject to change. Please see latest research for each company. * Historical prices are not split adjusted.